Novel Agents & Concepts in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer Webcast 048IC (2019)

This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

  • AbbVie
  • Amgen
  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genomic Health
  • Genentech
  • Merck
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologist
  • Resident
  • Advanced Practice Provider (Nurse Practitioners & Physician Assistants)

Learning Objectives

After completing this activity, participants will be able to:

  1. Diagnose both non-metastatic and metastatic castrate resistant prostate cancer (nmCRPC, mCRPC) and have a working knowledge of treatments and the proper order for administration.
  2. Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy.
  3. Analyze the mechanism of action and risks/benefits of using systemic agents in the treatment of nm/mCRPC.
  4. Describe the bone-targeted, radiopharmaceutical agent and its sequencing.
  5. Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
05/06/2019
Course expires: 
05/06/2020
Rating: 
0

Education Council Disclosures

PDF iconEducation Council Disclosures

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Judd Moul, MD, FACS

has no relevant financial relationships to disclose at this time.
Faculty(s)

Lawrence Karsh, MD, FACS

has no relevant financial relationships to disclose at this time.

Christopher Sweeney, MBBS

has no relevant financial relationships to disclose at this time.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2019
Expiration Date: May, 2020

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.